KRAS and neoplasm: Median progression-free survival was 12.0 months (95% CI: 6.6–17.5 months) in patients with wild-type KRAS tumours and 11.8 months (95% CI: 10.7–13.0 months) in those with mutant KRAS tumours (P= 0.985) (Figure 2).